Figure 2A demonstrates the interplay between the differentially expressed (DE) pathways, liver fibrosis, and genes after pioglitazone exposure, namely IFNG, NLRP3, and TGFBR2. The gene discussed is NLRP3; the disease is Hepatic fibrosis.